Tianjin Chase Sun PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 5/6

Tianjin Chase Sun PharmaceuticalLtd has a total shareholder equity of CN¥9.0B and total debt of CN¥803.8M, which brings its debt-to-equity ratio to 9%. Its total assets and total liabilities are CN¥11.4B and CN¥2.4B respectively. Tianjin Chase Sun PharmaceuticalLtd's EBIT is CN¥171.9M making its interest coverage ratio 5. It has cash and short-term investments of CN¥1.1B.

Key information

9.0%

Debt to equity ratio

CN¥803.83m

Debt

Interest coverage ratio	5x
Cash	CN¥1.12b
Equity	CN¥8.96b
Total liabilities	CN¥2.41b
Total assets	CN¥11.37b

Recent financial health updates

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Aug 02

Recent updates

We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings

Nov 01

Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects

Sep 26

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Aug 02

There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Jun 12

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

May 22

This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

May 21

Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 04

Financial Position Analysis

Short Term Liabilities: 300026's short term assets (CN¥6.3B) exceed its short term liabilities (CN¥1.7B).

Long Term Liabilities: 300026's short term assets (CN¥6.3B) exceed its long term liabilities (CN¥741.8M).

Debt to Equity History and Analysis

Debt Level: 300026 has more cash than its total debt.

Reducing Debt: 300026's debt to equity ratio has increased from 3.4% to 9% over the past 5 years.

Debt Coverage: 300026's debt is well covered by operating cash flow (129.7%).

Interest Coverage: 300026's interest payments on its debt are well covered by EBIT (5x coverage).

Tianjin Chase Sun PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 5/6

Key information

Recent financial health updates

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Recent updates

We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings

Third quarter 2024 earnings released: EPS: CN¥0.008 (vs CN¥0.051 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 15%

Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects

Second quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.06 in 2Q 2023)

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

Dividend of CN¥0.03 announced

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.06 in 1Q 2023)

Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

New minor risk - Earnings quality

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Tianjin Chase Sun Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2024

Full year 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.21 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.04 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.039 in 2Q 2022)

Tianjin Chase Sun Pharmaceutical Co.,Ltd. Approves Final Cash Dividend for A Shares for the Year 2022, Payable on 12 May 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.061 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.093 in 2Q 2021)

Investor sentiment improved over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 19, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Tianjin Chase Sun Pharmaceutical Co.,Ltd Approves Profit Distribution Proposal for 2021

Investor sentiment deteriorated over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 21, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Tianjin Chase Sun Pharmaceutical Co.,Ltd Proposes Cash Dividend for 2021

Investor sentiment improved over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.061 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.093 (vs CN¥0.067 in 2Q 2020)

Investor sentiment improved over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd Approves Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.19 (vs CN¥0.14 in FY 2019)

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥4.07

New 90-day low: CN¥4.26

New 90-day low: CN¥4.52

New 90-day low: CN¥5.01

Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces the Election of Li Li as an Independent Director

New 90-day low: CN¥5.27

Third quarter earnings released

New 90-day high - CN¥6.45

Earnings released

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 25, 2020

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies